JP2015524271A - Ul128複合体の送達及びcmv感染の予防のためのmvaワクチン - Google Patents
Ul128複合体の送達及びcmv感染の予防のためのmvaワクチン Download PDFInfo
- Publication number
- JP2015524271A JP2015524271A JP2015524249A JP2015524249A JP2015524271A JP 2015524271 A JP2015524271 A JP 2015524271A JP 2015524249 A JP2015524249 A JP 2015524249A JP 2015524249 A JP2015524249 A JP 2015524249A JP 2015524271 A JP2015524271 A JP 2015524271A
- Authority
- JP
- Japan
- Prior art keywords
- mva
- vaccine
- hcmv
- ul128c
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、National Institute of Allergy and Infectious Diseasesによって拠出された助成金第AI063356号;及びNational Cancer Instituteによって拠出された助成金第CA030206号の下で、政府の助成を受けて行われた。政府は、本発明において一定の権利を有する。
本願は、その全体が参照により本明細書に組み込まれる、2012年7月27日出願の米国仮特許出願第61/676,846号の利益を主張する。
本明細書に記載される実施形態によれば、HCMV抗原性タンパク質発現系(又は「抗原発現系」)が、本明細書に提供される。一実施形態では、この抗原発現系は、1つ又は複数のHCMV抗原性タンパク質又はその抗原断片を発現することが可能な発現ベクターをクローニングするための、クローニングベクターを含み得る。
上記抗原発現系は、細胞又は細胞の集団中へのHCMV侵入を予防する、in vitro、in vivo又はex vivoの方法において使用され得る。いくつかの実施形態では、細胞又は細胞の集団中へのHCMV侵入を予防するための方法は、この細胞又は細胞の集団を、UL128複合体又はその抗原断片を発現することが可能なウイルスベクターの有効量と接触させるステップを含む。
以下の実施例は、HCMV UL128Cの5つ全てのメンバーが、Epi/EC細胞感染を予防するNAbを刺激するために、臨床的に適切なMVAベクターのBAC由来バージョンにおいて同時に発現され得ることを示している。これらの実施例は以下の観察を少なくとも含む:(1)BACテクノロジーは、単一細胞においてRhCMV UL128Cを効率的に発現するようにMVAを迅速に操作するために適用され得る;(2)MVA−RhCMV−UL128CによるRMの免疫は、生物学的に適切な力価の、RhCMV上皮向性株を中和するNAbを惹起する;(3)BACテクノロジーは、単一細胞において機能的な5つのメンバーのHCMV UL128Cを発現するのに有効である;(4)臨床的に承認された1974−MVA株は、BAC中にクローニングできる;及び(5)HCMVによるヒトEpi/EC細胞の感染を遮断するNAbの発達を分析するためのRhCMV陰性RMの使用、(6)RMにおけるチャレンジ結果。(7)MVA中のHCMV UL128Cは、ARPE細胞に対する異なるHCMV Epi/EC向性株(TB40/E、VHL−1、TRなど)を中和するNAbをマウスにおいて惹起する。
ウイルス及び細胞。ベビーハムスター腎臓(BHK)細胞におけるMVAの繁殖並びにウイルスストックの調製及び保存を、以前に報告されたプロトコル(Wangら、2010)に従って実施した。MVA繁殖のためのニワトリ胚線維芽細胞(CEF)を、ウイルス生成無血清培地(VP−SFM;Invitrogen)中で維持した。
ヒトUL128CサブユニットのMVA発現。ヒトUL128、UL130、UL131、gL及びgHの全長5サブユニットペンタマーを発現するMVA(H−UL128C−MVA)を、実施例1に記載されるのと同様に、BACテクノロジーによって生成した。
動物及び免疫レジメン。合計200匹の雌性BALB/cマウス(月齢>2)が、本実施例及び以下の実施例に記載される候補抗原の発現及び体液性免疫原性を確認するために使用され得る。このアプローチは、感受性ヒト細胞株のin vitro HCMV感染を阻害するNAbについて、免疫したマウス由来の血清を評価するためであり得る。マウスは、rMVAでワクチン接種され得、予定された採血が、NAb生成を評価するために使用され得る。
動物及び免疫レジメン。動物は、California National Primate Research Center(CNPRC)における屋外の囲いにおけるRhCMV未感染飼育コホートに由来し得る。以下に記載する研究で使用する動物は、このプロジェクトの各別々の構成要素のために共収容される。これは、最小に侵襲性の手順を用いた非終末研究であり、動物は、研究の完了の時点でCNPRCコロニーに戻され得る。およそ等しい数の雄性及び雌性が使用され得るが、動物の性別は、これらの研究に含めるため又はこれらの研究から排除するための決定的要因ではない。
以下に列挙する参考文献、特許及び公開された特許出願、並びに上記明細書中で引用された全ての参考文献は、本明細書中に完全に示されるかのように、その全体が参照によって本明細書に組み込まれる。
Abel,K.、J.Martinez、Y.Yue、S.F.Lacey、Z.Wang、L.Strelow、A.Dasgupta、Z.Li、K.A.Schmidt、K.L.Oxford、B.Assaf、J.A.Longmate、D.J.Diamond及びP.A.Barry.2011.Vaccine−induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.J.Virol.85:2878〜2890.
Abel,K.、L.Strelow、Y.Yue、M.K.Eberhardt、K.A.Schmidt及びP.A.Barry.2008.A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.Vaccine 26:6013〜6025.
Adler SP、Nigro G、Pereira L.Recent advances in the prevention and treatment of congenital cytomegalovirus infections.Semin Perinatol.2007;31:10〜18.
Adler SP、Nigro G.Interrupting intrauterine transmission of cytomegalovirus.Rev Med Virol.2006;16:69〜71.
Adler,B.、L.Scrivano、Z.Ruzcics、B.Rupp、C.Sinzger及びU.Koszinowski.2006.Role of human cytomegalovirus UL131A in cell type−specific virus entry and release.J.Gen.Virol.87:2451〜2460.
Adler,S.P.、S.E.Starr、S.A.Plotkin、S.H.Hempfling、J.Buis、M.L.Manning及びA.M.Best.1995.Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.J.Infect.Dis.171:26〜32.
Adler,S.P.、S.H.Hempfling、S.E.Starr、S.A.Plotkin及びS.Riddell.1998.Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.Pediatr.Infect.Dis.J.17:200〜206.
Arvin,A.M.、P.Fast、M.Myers、S.Plotkin及びR.Rabinovich.2004.Vaccine development to prevent cytomegalovirus disease:report from the National Vaccine Advisory Committee.Clin.Infect.Dis.39:233〜239.
Assaf,B.T.、K.G.Mansfield、S.V.Westmoreland、A.Kaur、K.L.Oxford、D.J.Diamond及びP.A.Barry.2012.Patterns of Acute Rhesus Cytomegalovirus(RhCMV)Infection Predict Long−Term RhCMV Infection.J.Virol.86:6354〜6357.
Barry PA、Chang W−LW.Primate Betaherpesviruses.In:Arvin A、Campadielli G、Moore P、Mocarski ES、Roizman B、Whitley RJら編、Human Herpesviruses:biology,Therapy,and immunoprophylaxis.Cambridge:Cambridge University press;2007:1051〜1075.
Barry PA、Strelow LI.2012 Development of Breeding Populations of Rhesus Macaques That Are Specific Pathogen Free for Rhesus Cytomegalovirus.Comparative Medicine.58:43〜46..
Barry,P.A.、K.M.Lockridge、S.Salamat、S.P.Tinling、Y.Yue、S.S.Zhou、S.M.Gospe,Jr.、W.J.Britt及びA.F.Tarantal.2006.Nonhuman primate models of intrauterine cytomegalovirus infection.ILAR.J.47:49〜64.
Bernstein,D.I.、E.A.Reap、K.Katen、A.Watson、K.Smith、P.Norberg、R.A.Olmsted、A.Hoeper、J.Morris、S.Negri、M.F.Maughan及びJ.D.Chulay.2009.Randomized,double−blind,Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.Vaccine 28:484〜493.
Boppana SB、Britt WJ.Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.J Infect Dis.1995;171:1115〜1121.
Boppana SB、Rivera LB、Fowler KB、Mach M、Britt WJ.Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.N Engl J Med.2001;344:1366〜1371.
Britt W.Manifestations of human cytomegalovirus infection:proposed mechanisms of acute and chronic disease.Curr Top Microbiol Immunol.2008;325:417〜470.
Britt WJ、Vugler L、Stephens EB.Induction of complement−dependent and −independent neutralizing antibodies by recombinant−derived human cytomegalovirus gp55−116(gB).J Virol.1988;62:3309〜3318.
Britt,W.J.、L.Vugler、E.J.Butfiloski及びE.B.Stephens.1990.Cell surface expression of human cytomegalovirus(HCMV)gp55−116(gB):use of HCMV−recombinant vaccinia virus−infected cells in analysis of the human neutralizing antibody response.J.Virol.64:1079〜1085.
Britt WJ.Neutralizing antibodies detect a disulfide−linked glycoprotein complex within the envelope of human cytomegalovirus.Virology.1984;135:369〜378.
Cha TA、Tom E、Kemble GWら、Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.J Virol.1996;70:78〜83.
Cottingham MG、Gilbert SC.Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self−excising bacterial artificial chromosome.J Virol Methods.2010;168:233〜236.
Cottingham,M.G.、R.F.Andersen、A.J.Spencer、S.Saurya、J.Furze、A.V.Hill及びS.C.Gilbert.2008.Recombination−mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara(MVA).PLoS.One.3:e1638.
Cui,X.、B.P.Meza、S.P.Adler及びM.A.McVoy.2008.Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.Vaccine 26:5760〜5766.
Domi,A.及びB.Moss.2002.Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells.Proc.Natl.Acad.Sci.U.S.A 99:12415〜12420.
Dunn W、Chou C、Li Hら、Functional profiling of a human cytomegalovirus genome.Proc Natl Acad Sci U S A.2003;100:14223〜14228.
Earl PL、Americo JL、Wyatt LSら、Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long−term immunity to an orthopoxvirus in a non−human primate.Virology.2007;366:84〜97.
Earl,P.L.、B.Moss、L.S.Wyatt及びM.W.Carroll.2001.Generation of recombinant vaccinia viruses.Curr.Protoc.Mol.Biol.第16章:ユニット16.
Endresz,V.、K.Burian、K.Berencsi、Z.Gyulai、L.Kari、H.Horton、D.Virok、C.Meric、S.A.Plotkin及びE.Gonczol.2001.Optimization of DNA immunization against human cytomegalovirus.Vaccine 19:3972〜3980.
Fouts,A.E.、P.Chan、J.P.Stephan、R.Vandlen及びB.Feierbach.2012.Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti−CMV neutralizing antibody response in CMV−HIG.J.Virol.86:7444〜7447.
Genini,E.、E.Percivalle、A.Sarasini、M.G.Revello、F.Baldanti及びG.Gerna.2011.Serum antibody response to the gH/gL/pUL128−131 five−protein complex of human cytomegalovirus(HCMV)in primary and reactivated HCMV infections.J.Clin.Virol.52:113〜118.
Gerna,G.、A.Sarasini、M.Patrone、E.Percivalle、L.Fiorina、G.Campanini、A.Gallina、F.Baldanti及びM.G.Revello.2008.Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells,but not fibroblasts,early during primary infection.J.Gen.Virol.89:853〜865.
Gonczol E、Ianacone J、Ho WZら、Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune−responses in human volunteers.Vaccine.1990;8:130〜136.
Gonczol E、Plotkin S.Development of a cytomegalovirus vaccine:lessons from recent clinical trials.Expert Opin Biol Ther.2001;1:401〜412.
Grazia RM、Baldanti F、Percivalle Eら、In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells.J Gen Virol.2001;82:1429〜1438.
Griffiths,P.D.、A.Stanton、E.McCarrell、C.Smith、M.Osman、M.Harber、A.Davenport、G.Jones、D.C.Wheeler、J.O’Beirne、D.Thorburn、D.Patch、C.E.Atkinson、S.Pichon、P.Sweny、M.Lanzman、E.Woodford、E.Rothwell、N.Old、R.Kinyanjui、T.Haque、S.Atabani、S.Luck、S.Prideaux、R.S.Milne、V.C.Emery及びA.K.Burroughs.2011.Cytomegalovirus glycoprotein−B vaccine with MF59 adjuvant in transplant recipients:a phase 2 randomised placebo−controlled trial.Lancet 377:1256〜1263.
Hahn,G.、M.G.Revello、M.Patrone、E.Percivalle、G.Campanini、A.Sarasini、M.Wagner、A.Gallina、G.Milanesi、U.Koszinowski、F.Baldanti及びG.Gerna.2004.Human cytomegalovirus UL131−128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes.J.Virol.78:10023〜10033.
Hanke T、McMichael AJ、Dennis MJら、Biodistribution and persistence of an MVA−vectored candidate HIV vaccine in SIV−infected rhesus macaques and SCID mice.Vaccine.2005;23:1507〜1514.
Hansen SG、Powers CJ、Richards Rら、Evasion of CD8+T cells is critical for superinfection by cytomegalovirus.Science.2010;328:102〜106.
Hansen,S.G.、L.I.Strelow、D.C.Franchi、D.G.Anders及びS.W.Wong.2003.Complete sequence and genomic analysis of rhesus cytomegalovirus.J.Virol.77:6620〜6636.
Heineman TC、Schleiss M、Bernstein DIら、A phase 1 study of 4 live,recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.J Infect Dis.2006;193:1350〜1360.
Huff,J.L.、R.Eberle、J.Capitanio、S.S.Zhou及びP.A.Barry.2003.Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques.J.Gen.Virol.84:83〜92.
Isaacson,M.K.及びT.Compton.2009.Human cytomegalovirus glycoprotein B is required for virus entry and cell−to−cell spread but not for virion attachment,assembly,or egress.J.Virol.83:3891〜3903.
Jarvis MA、Nelson JA.Molecular basis of persistence and latency.Human Herpesviruses:Biology,Therapy,and Immunoprophylaxis.Cambridge:Cambridge University Press;2007.
Johnson,D.C.及びP.G.Spear.1983.O−linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus.Cell 32:987〜997.
Kharfan−Dabaja,M.A.、M.Boeckh、M.B.Wilck、A.A.Langston、A.H.Chu、M.K.Wloch、D.F.Guterwill、L.R.Smith、A.P.Rolland及びR.T.Kenney.2012.A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem−cell transplantation:a randomised,double−blind,placebo−controlled,phase 2 trial.Lancet Infect.Dis.12:290〜299.
Kinzler ER、Compton T.Characterization of human cytomegalovirus glycoprotein−induced cell−cell fusion.J Virol.2005;79:7827〜7837.
La Torre R、Nigro G、Mazzocco M、Best AM、Adler SP.Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease.Clin Infect Dis.2006;43:994〜1000.
Lanzavecchiaら、米国特許出願公開第2009/0081230号
Lilja,A.E.及びT.Shenk.2008.Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types.Proc.Natl.Acad.Sci.U.S.A 105:19950〜19955.
Lilleri D、Fornara C、Furione Mら、Development of Human Cytomegalovirus−Specific T Cell Immunity during Primary Infection of Pregnant Women and Its Correlation with Virus Transmission to the Fetus.J Infect Dis.2007;195:1062〜1070.
Liu YN、Klaus A、Kari Bら、The N−terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B− and T−cell immune responses in humans.J Virol.1991;65:1644〜1648.
Lubaki MN、Egan MA、Siliciano RF、Weinhold KJ、Bollinger RC.A novel method for detection and ex vivo expansion of HIV type 1−specific cytolytic T lymphocytes.AIDS Res Hum Retroviruses.1994;10:1427〜1431.
Macagno,A.、N.L.Bernasconi、F.Vanzetta、E.Dander、A.Sarasini、M.G.Revello、G.Gerna、F.Sallusto及びA.Lanzavecchia.2010.Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128−131A complex.J.Virol.84:1005〜1013.
Maidji E、McDonagh S、Genbacev O、Tabata T、Pereira L.Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor−mediated transcytosis.Am J Pathol.2006;168:1210〜1226.
Maidji E、Percivalle E、Gerna G、Fisher S、Pereira L.Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts.Virology.2002;304:53〜69.
Mansat A、Mengelle C、Chalet Mら、Cytomegalovirus detection in cryopreserved semen samples collected for therapeutic donor insemination.Hum Reprod.1997;12:1663〜1666.
Manuel,E.R.、Z.Wang、Z.Li、R.C.La、W.Zhou及びD.J.Diamond.2010.Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen−specific immune responses.Virology 403:155〜162.
Marshall,G.S.、G.G.Stout、M.E.Knights、G.P.Rabalais、R.Ashley、H.Miller及びE.Rossier.1994.Ontogeny of glycoprotein gB−specific antibody and neutralizing activity during natural cytomegalovirus infection.J.Med.Virol.43:77〜83.
Mayr,A.及びK.Malicki.1966.[Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus].Zentralbl.Veterinarmed.B13:1〜13.
Murphy,E.、D.Yu、J.Grimwood、J.Schmutz、M.Dickson、M.A.Jarvis、G.Hahn、J.A.Nelson、R.M.Myers及びT.E.Shenk.2003.Coding potential of laboratory and clinical strains of human cytomegalovirus.Proc.Natl.Acad.Sci.U.S.A 100:14976〜14981.
Navarro D、Paz P、Tugizov Sら、Glycoprotein B of human cytomegalovirus promotes virion penetration into cells,transmission of infection from cell to cell,and fusion of infected cells.Virology.1993;197:143〜158.
Nigro G、Torre RL、Pentimalli Hら、Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy.Prenat Diagn.2008;28:512〜517.
Nigro,G.、S.P.Adler、T.R.La及びA.M.Best.2005.Passive immunization during pregnancy for congenital cytomegalovirus infection.N.Engl.J.Med.353:1350〜1362.
Oxford,K.L.、L.Strelow、Y.Yue、W.L.Chang、K.A.Schmidt、D.J.Diamond及びP.A.Barry.2011.Open reading frames carried on UL/b’ are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys.J.Virol.85:5105〜5114.
Oxford,K.L.、M.K.Eberhardt、K.W.Yang、L.Strelow、S.Kelly、S.S.Zhou及びP.A.Barry.2008.Protein coding content of the UL)b’ region of wild−type rhesus cytomegalovirus.Virology 373:181〜188.
Oxford,K.L.、M.K.Eberhardt、K.W.Yang、L.Strelow、S.Kelly、S.S.Zhou及びP.A.Barry.2008.Protein coding content of the UL)b’ region of wild−type rhesus cytomegalovirus.Virology 373:181〜188.
Pass,R.F.、A.M.Duliege、S.Boppana、R.Sekulovich、S.Percell、W.Britt及びR.L.Burke.1999.A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.J.Infect.Dis.180:970〜975.
Pass,R.F.、C.Zhang、A.Evans、T.Simpson、W.Andrews、M.L.Huang、L.Corey、J.Hill、E.Davis、C.Flanigan及びG.Cloud.2009.Vaccine prevention of maternal cytomegalovirus infection.N.Engl.J.Med.360:1191〜1199.
Patrone M、Secchi M、Fiorina Lら、Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.J Virol.2005;79:8361〜8373.
Plachter B、Sinzger C、Jahn G.Cell types involved in replication and distribution of human cytomegalovirus.Adv Virus Res.1996;46:195〜261.
Plotkin SA、Furukawa T、Zygraich N、Huygelen C.Candidate cytomegalovirus strain for human vaccination.Infect Immun.1975;12:521〜527.
Plotkin SA、Starr SE、Friedman HMら、Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant.A controlled trial[コメントを参照のこと].Ann Intern Med.1991;114:525〜531.
Plotkin SA、Starr SE、Friedman HM、Gonczol E、Weibel RE.Protective effects of Towne cytomegalovirus vaccine against low−passage cytomegalovirus administered as a challenge.J Infect Dis.1989;159:860〜865.
Rasmussen,L.、C.Matkin、R.Spaete、C.Pachl及びT.C.Merigan.1991.Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans.J.Infect.Dis.164:835〜842.
Revello,M.G.及びG.Gerna.2010.Human cytomegalovirus tropism for endothelial/epithelial cells:scientific background and clinical implications.Rev.Med.Virol.20:136〜155.
Rivailler,P.、A.Kaur、R.P.Johnson及びF.Wang.2006.Genomic sequence of rhesus cytomegalovirus 180.92:insights into the coding potential of rhesus cytomegalovirus.J.Virol.80:4179〜4182.
Ryckman BJ、Jarvis MA、Drummond DD、Nelson JA、Johnson DC.Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low−pH fusion.J Virol.2006;80:710〜722.
Ryckman,B.J.、B.L.Rainish、M.C.Chase、J.A.Borton、J.A.Nelson、M.A.Jarvis及びD.C.Johnson.2008b.Characterization of the human cytomegalovirus gH/gL/UL128−131 complex that mediates entry into epithelial and endothelial cells.J.Virol.82:60〜70.
Ryckman,B.J.、M.C.Chase及びD.C.Johnson.2008a.HCMV gH/gL/UL128−131 interferes with virus entry into epithelial cells:evidence for cell type−specific receptors.Proc.Natl.Acad.Sci.U.S.A 105:14118〜14123.
Ryckman,B.J.、M.C.Chase及びD.C.Johnson.2010.Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions.J.Virol.84:2597〜2609.
Saccoccio F、Sauer A、Cui Xら、2011.Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.Vaccine.29:2705〜2711.
Saccoccio,F.M.、A.L.Sauer、X.Cui、A.E.Armstrong、e.Habib、D.C.Johnson、B.J.Ryckman、A.J.Klingelhutz、S.P.Adler及びM.A.McVoy.2011.Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.Vaccine 29:2705〜2711.
Schleiss MR.Role of breast milk in acquisition of cytomegalovirus infection:recent advances.Curr Opin Pediatr.2006a;18:48〜52.
Schleiss,M.R.2006b.Nonprimate models of congenital cytomegalovirus(CMV)infection:gaining insight into pathogenesis and prevention of disease in newborns.ILAR.J.47:65〜72.
Schleiss,M.R.2010.Cytomegalovirus vaccines and methods of production(WO20009049138号):the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface.Expert.Opin.Ther.Pat 20:597〜602.
Schleiss,M.R.、A.McGregor、K.Y.Choi、S.V.Date、X.Cui及びM.A.McVoy.2008.Analysis of the nucleotide sequence of the guinea pig cytomegalovirus(GPCMV)genome.Virol.J.5:139.
Sequar,G.、W.J.Britt、F.D.Lakeman、K.M.Lockridge、R.P.Tarara、D.R.Canfield、S.S.Zhou、M.B.Gardner及びP.A.Barry.2002.Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus:pathogenesis.J.Virol.76:7661〜7671.
Shenkら、米国特許出願公開第2008/0187545号.
Shimamura,M.、M.Mach及びW.J.Britt.2006.Human cytomegalovirus infection elicits a glycoprotein M(gM)/gN−specific virus−neutralizing antibody response.J.Virol.80:4591〜4600.
Sinzger,C.、M.Digel及びG.Jahn.2008.Cytomegalovirus cell tropism.Curr.Top.Microbiol.Immunol.325:63〜83.
Stagno S、Reynolds D、Tsiantos Aら、Cervical cytomegalovirus excretion in pregnant and nonpregnant women:suppression in early gestation.J Infect Dis.1975;131:522〜527.
Stratton,K.R.、J.S.Durch及びR.S.Lawrence.2001.Vaccines for the 21st Century:A tool for Decisionmaking.Bethesda:National Academy Press.
Timm A、Enzinger C、Felder E、Chaplin P.Genetic stability of recombinant MVA−BN.Vaccine.2006;24:4618〜4621.
Tischer,B.K.、E.J.von、B.Kaufer及びN.Osterrieder.2006.Two−step red−mediated recombination for versatile high−efficiency markerless DNA manipulation in Escherichia coli.Biotechniques 40:191〜197.
Tischer,B.K.、G.A.Smith及びN.Osterrieder.2010.En passant mutagenesis:a two step markerless red recombination system.Methods Mol.Biol.634:421〜430.
Urban,M.、M.Klein、W.J.Britt、E.Hassfurther及びM.Mach.1996.Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response.J.Gen.Virol.77(パート7):1537〜1547.
van Kooten,C.及びJ.Banchereau.2000.CD40−CD40 ligand.J.Leukoc.Biol.67:2〜17.
Vanarsdall,A.L.及びD.C.Johnson.2012.Human cytomegalovirus entry into cells.Curr.Opin.Virol.2:37〜42.
Vanarsdall,A.L.、B.J.Ryckman、M.C.Chase及びD.C.Johnson.2008.Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell−cell fusion when expressed either in cis or in trans.J.Virol.82:11837〜11850.
Wang D、Li F、Freed DCら、Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.Vaccine.2011.29:9075〜9080.
Wang Z、La Rosa C、Lacey SFら、Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.J Clin Virol.2006;35:324〜331.
Wang Z、La Rosa C、Mekhoubad Sら、Attenuated Poxviruses Generate Clinically Relevant Frequencies of CMV−Specific T cells.Blood.2004;104:847〜856.
Wang Z、Zhou W、Srivastava Tら、A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.Virology.2008;377:379〜390.
Wang,D.及びT.Shenk.2005a.Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism.J.Virol.79:10330〜10338.
Wang,D.及びT.Shenk.2005b.Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.Proc.Natl.Acad.Sci.U.S.A 102:18153〜18158.
Wang,Z.、J.Martinez、W.Zhou、R.C.La、T.Srivastava、A.Dasgupta、R.Rawal、Z.Li、W.J.Britt及びD.Diamond.2010.Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.Vaccine 28:1547〜1557.
Wang,Z.、R.C.La、R.Maas、H.Ly、J.Brewer、S.Mekhoubad、P.Daftarian、J.Longmate、W.J.Britt及びD.J.Diamond.2004.Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.J.Virol.78:3965〜3976.
Wang,Z.、R.C.La、Z.Li、H.Ly、A.Krishnan、J.Martinez、W.J.Britt及びD.J.Diamond.2007.Vaccine properties of a novel marker gene−free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.Vaccine 25:1132〜1141.
Wilck MB、Chu A、Wloch Mら、Interim Analysis of a Phase 2 Trial of TransVax(商標),a Therapeutic DNA Vaccine for Control of Cytomegalovirus in Transplant Recipients[要約].ICAAC.2010.
Wille,P.T.、A.J.Knoche、J.A.Nelson、M.A.Jarvis及びD.C.Johnson.2010.A human cytomegalovirus gO−null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells.J.Virol.84:2585〜2596.
Wloch MK、Smith LR、Boutsaboualoy Sら、Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.J Infect Dis.2008;197:1634〜1642.
Wussow F、Yue Y、Martinez J、Deere JD、Longmate J、Herrmann A、Barry PA、Diamond DJ.2013.A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.J Virol.2013年2月;87(3):1322〜32.
Wyatt,L.S.、P.L.Earl、W.Xiao、J.L.Americo、C.A.Cotter、J.Vogt及びB.Moss.2009.Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.J.Virol.83:7176〜7184.
Yamada,S.、N.Nozawa、H.Katano、Y.Fukui、M.Tsuda、Y.Tsutsui、I.Kurane及びN.Inoue.2009.Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate−early genes,UL128,and UL130.Virology 391:99〜106.
Yu D、Silva MC、Shenk T.Functional map of human cytomegalovirus AD169 defined by global mutational analysis.Proc Natl Acad Sci U S A.2003;100:12396〜12401.
Yue,Y.及びP.A.Barry.2008.Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus.Adv.Virus Res.72:207〜226.
Yue,Y.、S.S.Zhou及びP.A.Barry.2003.Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.J.Gen.Virol.84:3371〜3379.
Yue,Y.、Z.Wang、K.Abel、J.Li、L.Strelow、A.Mandarino、M.K.Eberhardt、K.A.Schmidt、D.J.Diamond及びP.A.Barry.2008.Evaluation of recombinant modified vaccinia Ankara virus−based rhesus cytomegalovirus vaccines in rhesus macaques.Med.Microbiol.Immunol.197:117〜123.
Zhang,C.及びR.F.Pass.2004.Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.Vaccine 23:507〜510.
Zhang,C.、H.Buchanan、W.Andrews、A.Evans及びR.F.Pass.2006.Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women:seroconversion and viral shedding.J.Clin.Virol.35:338〜342.
Claims (27)
- 細菌人工染色体(BAC)構築物を含む発現系であって、前記BAC構築物が、UL128複合体をコードするDNA配列のセットが挿入されたウイルスベクターを含む、発現系。
- 前記ウイルスベクターが、アビポックスウイルス、オルソポックスウイルス又はパラポックスウイルスに由来する、請求項1に記載の発現系。
- 前記ウイルスベクターが、改変ワクシニアアンカラ(MVA)ベクターである、請求項2に記載の発現系。
- 前記UL128複合体が、5つのCMVタンパク質又はその抗原断片のセットを含む、請求項1に記載の発現系。
- 前記5つのCMVタンパク質又はその抗原断片のセットが、UL128、UL130、UL131A、gL及びgHである、請求項3に記載の発現系。
- 前記ウイルスベクターに、pp65、gB又はその両方から選択される1つ又は複数のさらなるCMVタンパク質又はその抗原断片をコードする、1つ又は複数のさらなるDNA配列がさらに挿入されている、請求項1に記載の発現系。
- UL128複合体を発現することが可能なウイルスベクター、及び、薬学的に許容される担体、アジュバント、添加剤又はその組合せを含む、CMV感染を予防するためのワクチン組成物。
- 前記ウイルスベクターが、前記UL128複合体をコードするDNA配列のセットを含む、請求項7に記載のワクチン。
- 前記ウイルスベクターが、アビポックスウイルス、オルソポックスウイルス又はパラポックスウイルスに由来する、請求項7に記載のワクチン。
- 前記ウイルスベクターが、改変ワクシニアアンカラ(MVA)ベクターである、請求項9に記載のワクチン。
- 前記UL128複合体が、CMVタンパク質又はその抗原断片のセットを含む、請求項7に記載のワクチン。
- 前記5つのCMVタンパク質又はその抗原断片のセットが、UL128、UL130、UL131A、gL及びgHを含む、請求項11に記載のワクチン。
- 前記ウイルスベクターが、pp65、gB又はその両方から選択される1つ又は複数のさらなるCMVタンパク質又はその抗原断片を発現することが可能である、請求項7に記載のワクチン。
- 細胞中へのCMV侵入を予防する方法であって、前記細胞を有効量のウイルスベクターと接触させるステップを含み、前記ウイルスベクターが、UL128複合体をコードするDNA配列のセットを含む、方法。
- 前記ウイルスベクターが、細菌人工染色体(BAC)に由来するポックスウイルスベクターを含む、請求項14に記載の方法。
- 前記ウイルスベクターが、細菌人工染色体(BAC)に由来するMVAベクターを含む、請求項14に記載の方法。
- 前記UL128複合体が、5つのCMVタンパク質又はその抗原断片のセットを含む、請求項14に記載の方法。
- 前記5つのCMVタンパク質又はその抗原断片のセットが、UL128、UL130、UL131A、gL及びgHである、請求項14に記載の方法。
- pp65、gB若しくはその両方から、又はgM/gN及びgOから選択されるさらなるCMVタンパク質又はその抗原断片をコードする1つ又は複数のDNA配列をさらに含む、請求項14に記載の方法。
- 前記細胞が、上皮細胞、内皮細胞又は線維芽細胞である、請求項14に記載の方法。
- 対象においてCMV感染を処置する方法であって、治療有効量のCMVワクチンを前記対象に投与するステップを含み、前記CMVワクチンが、UL128複合体を発現することが可能なウイルスベクター、及び、薬学的に許容される担体、アジュバント、添加剤又はその組合せを含む、方法。
- 前記ウイルスベクターが、アビポックスウイルス、オルソポックスウイルス又はパラポックスウイルスに由来する、請求項21に記載の方法。
- 前記ウイルスベクターがMVAベクターである、請求項22に記載の方法。
- 前記UL128複合体が、5つのCMVタンパク質又はその抗原断片のセットを含む、請求項21に記載の方法。
- 前記5つのCMVタンパク質又はその抗原断片のセットが、UL128、UL130、UL131A、gL及びgHを含む、請求項24に記載の方法。
- 前記ウイルスベクターが、pp65、gB又はその両方から選択されるさらなるCMVタンパク質又はその抗原断片をコードする1つ又は複数のDNA配列をさらに含む、請求項21に記載の方法。
- 前記CMV感染が先天性CMV感染である、請求項21に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676846P | 2012-07-27 | 2012-07-27 | |
US61/676,846 | 2012-07-27 | ||
PCT/US2013/032554 WO2014018117A1 (en) | 2012-07-27 | 2013-03-15 | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018191448A Division JP6706656B2 (ja) | 2012-07-27 | 2018-10-10 | Ul128複合体の送達及びcmv感染の予防のためのmvaワクチン |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015524271A true JP2015524271A (ja) | 2015-08-24 |
JP2015524271A5 JP2015524271A5 (ja) | 2016-02-04 |
JP6419695B2 JP6419695B2 (ja) | 2018-11-07 |
Family
ID=49997707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015524249A Active JP6419695B2 (ja) | 2012-07-27 | 2013-03-15 | Ul128複合体の送達及びcmv感染の予防のためのmvaワクチン |
JP2018191448A Active JP6706656B2 (ja) | 2012-07-27 | 2018-10-10 | Ul128複合体の送達及びcmv感染の予防のためのmvaワクチン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018191448A Active JP6706656B2 (ja) | 2012-07-27 | 2018-10-10 | Ul128複合体の送達及びcmv感染の予防のためのmvaワクチン |
Country Status (9)
Country | Link |
---|---|
US (5) | US9931395B2 (ja) |
EP (1) | EP2877580B1 (ja) |
JP (2) | JP6419695B2 (ja) |
CN (3) | CN116376983A (ja) |
AU (2) | AU2013293570B2 (ja) |
CA (1) | CA2879577C (ja) |
DK (1) | DK2877580T3 (ja) |
ES (1) | ES2719720T3 (ja) |
WO (1) | WO2014018117A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019535665A (ja) * | 2016-10-21 | 2019-12-12 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
JP2020533354A (ja) * | 2017-09-13 | 2020-11-19 | サノフィ・パスツールSanofi Pasteur | ヒトサイトメガロウイルス免疫原性組成物 |
CN112888455A (zh) * | 2018-10-25 | 2021-06-01 | Km生物医薬股份公司 | 修饰CMVgB蛋白及包含其的CMV疫苗 |
JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス(cmv)抗原の発現のためのmvaベクター及びその使用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
CN116376983A (zh) | 2012-07-27 | 2023-07-04 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
CA2931140C (en) * | 2014-02-05 | 2022-08-30 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Error-free sequencing of dna |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
US20170119874A1 (en) * | 2014-04-23 | 2017-05-04 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
EP3347045A4 (en) * | 2015-09-10 | 2019-08-28 | City of Hope | ANTIBODIES GENERATED BY MVA-GH / GL-PC VACCINE NEUTRALIZING THE INFECTIOUS POWER OF HUMAN CYTOMEGALOVIRUS AND ASSOCIATED METHODS |
MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
WO2019014569A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS |
EP3790578A4 (en) * | 2018-05-11 | 2022-04-06 | City of Hope | GENETICALLY MODIFIED RECOMBINANT VACCINIA-ANKARA (RMVA) VACCINE WITH IMPROVED STABILITY AND METHODS FOR THEIR PRODUCTION |
US20220143174A1 (en) * | 2019-02-22 | 2022-05-12 | City Of Hope | Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof |
EP3963056A4 (en) * | 2019-05-02 | 2023-01-25 | The Regents of the University of California | VACCINATION USING HERPESVIRUS GENOMES IN NUCLEIC ACID FORM |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112961879A (zh) * | 2021-02-26 | 2021-06-15 | 江南大学 | 一种n-乙酰神经氨酸生产稳定性提高的重组枯草芽孢杆菌 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009539845A (ja) * | 2006-06-07 | 2009-11-19 | トラスティーズ オブ プリンストン ユニバーシティ | ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 |
US20100316667A1 (en) * | 2009-06-05 | 2010-12-16 | Don Diamond | Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof |
JP2011500592A (ja) * | 2007-10-10 | 2011-01-06 | ザ トラスティーズ オブ プリンストン ユニバーシティー | サイトメガロウイルスワクチンおよび製造方法 |
JP2011527899A (ja) * | 2008-07-16 | 2011-11-10 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | ヒトサイトメガロウイルス中和抗体およびその使用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
US20030009013A1 (en) | 1998-12-30 | 2003-01-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
WO2004026910A1 (en) | 2002-09-20 | 2004-04-01 | Lupin Ltd | Monoclonal antibody derived peptide inhibitors for mycobacterial dna gyrase |
JPWO2004076663A1 (ja) | 2003-02-27 | 2006-06-08 | 独立行政法人産業技術総合研究所 | 哺乳動物細胞におけるdsRNAによるCpG配列へのメチル化誘導 |
WO2004093905A1 (en) | 2003-04-16 | 2004-11-04 | City Of Hope | Human cytomegalovirus antigens expressed in mva and methods of use |
US7976845B2 (en) | 2004-11-29 | 2011-07-12 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
CN103255110B (zh) | 2006-08-25 | 2016-04-20 | 美国国有健康与人类服务部(马里兰州) | 修饰的安卡拉痘苗病毒基因的基因组中保守基因之间的基因间位点 |
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
KR101597842B1 (ko) | 2008-01-11 | 2016-02-25 | 가부시키가이샤 진 테크노 사이언스 | 인간화된 항-알파9 인테그린 항체 및 그의 용도 |
PE20141432A1 (es) | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
WO2010014567A2 (en) | 2008-08-01 | 2010-02-04 | Merck & Co., Inc. | Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof |
EP2614072A4 (en) * | 2010-09-09 | 2014-03-19 | Univ Virginia Commonwealth | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
ES2716243T3 (es) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
KR20140007404A (ko) * | 2011-01-31 | 2014-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법 |
EP2691422B1 (en) * | 2011-03-29 | 2019-02-06 | UAB Research Foundation | Methods and compositions for cytomegalovirus il-10 protein |
TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗-hla-b*27抗體及其用途 |
CN104853771A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
CN116376983A (zh) | 2012-07-27 | 2023-07-04 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
-
2013
- 2013-03-15 CN CN202211543748.7A patent/CN116376983A/zh active Pending
- 2013-03-15 CA CA2879577A patent/CA2879577C/en active Active
- 2013-03-15 ES ES13822266T patent/ES2719720T3/es active Active
- 2013-03-15 WO PCT/US2013/032554 patent/WO2014018117A1/en active Application Filing
- 2013-03-15 EP EP13822266.6A patent/EP2877580B1/en active Active
- 2013-03-15 CN CN201910327043.3A patent/CN110241137A/zh active Pending
- 2013-03-15 DK DK13822266.6T patent/DK2877580T3/en active
- 2013-03-15 CN CN201380050859.7A patent/CN104838000B/zh active Active
- 2013-03-15 AU AU2013293570A patent/AU2013293570B2/en active Active
- 2013-03-15 JP JP2015524249A patent/JP6419695B2/ja active Active
-
2015
- 2015-01-27 US US14/606,973 patent/US9931395B2/en active Active
-
2018
- 2018-03-12 US US15/919,110 patent/US10376575B2/en active Active
- 2018-10-10 JP JP2018191448A patent/JP6706656B2/ja active Active
-
2019
- 2019-08-12 US US16/538,668 patent/US10842864B2/en active Active
- 2019-08-22 AU AU2019219819A patent/AU2019219819A1/en not_active Abandoned
-
2020
- 2020-11-20 US US17/100,573 patent/US11717568B2/en active Active
-
2023
- 2023-06-13 US US18/334,279 patent/US20230398209A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009539845A (ja) * | 2006-06-07 | 2009-11-19 | トラスティーズ オブ プリンストン ユニバーシティ | ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 |
JP2011500592A (ja) * | 2007-10-10 | 2011-01-06 | ザ トラスティーズ オブ プリンストン ユニバーシティー | サイトメガロウイルスワクチンおよび製造方法 |
JP2011527899A (ja) * | 2008-07-16 | 2011-11-10 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | ヒトサイトメガロウイルス中和抗体およびその使用 |
US20100316667A1 (en) * | 2009-06-05 | 2010-12-16 | Don Diamond | Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof |
Non-Patent Citations (2)
Title |
---|
MED MICROBIOL IMMUNOL, 2008, VOL.197, P.117-123, JPN6017004298, ISSN: 0003696018 * |
VACCINE, 2007, VOL.25, P.1132-1141, JPN6017004301, ISSN: 0003696019 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019535665A (ja) * | 2016-10-21 | 2019-12-12 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
JP2022024088A (ja) * | 2016-10-21 | 2022-02-08 | モデルナティエックス インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
JP2020533354A (ja) * | 2017-09-13 | 2020-11-19 | サノフィ・パスツールSanofi Pasteur | ヒトサイトメガロウイルス免疫原性組成物 |
JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス(cmv)抗原の発現のためのmvaベクター及びその使用 |
CN112888455A (zh) * | 2018-10-25 | 2021-06-01 | Km生物医薬股份公司 | 修饰CMVgB蛋白及包含其的CMV疫苗 |
Also Published As
Publication number | Publication date |
---|---|
DK2877580T3 (en) | 2019-04-23 |
AU2019219819A1 (en) | 2019-09-12 |
ES2719720T3 (es) | 2019-07-12 |
US11717568B2 (en) | 2023-08-08 |
US20210177962A1 (en) | 2021-06-17 |
CA2879577A1 (en) | 2014-01-30 |
US10376575B2 (en) | 2019-08-13 |
WO2014018117A1 (en) | 2014-01-30 |
CN110241137A (zh) | 2019-09-17 |
EP2877580A1 (en) | 2015-06-03 |
CN104838000A (zh) | 2015-08-12 |
AU2013293570A1 (en) | 2015-02-05 |
JP6706656B2 (ja) | 2020-06-10 |
US20180303930A1 (en) | 2018-10-25 |
AU2013293570B2 (en) | 2019-05-23 |
JP2019037235A (ja) | 2019-03-14 |
CN104838000B (zh) | 2022-12-20 |
US9931395B2 (en) | 2018-04-03 |
EP2877580B1 (en) | 2019-01-30 |
US10842864B2 (en) | 2020-11-24 |
CN116376983A (zh) | 2023-07-04 |
US20150216965A1 (en) | 2015-08-06 |
CA2879577C (en) | 2021-08-03 |
US20230398209A1 (en) | 2023-12-14 |
JP6419695B2 (ja) | 2018-11-07 |
EP2877580A4 (en) | 2016-04-20 |
US20200069791A1 (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11717568B2 (en) | MVA vaccine for delivery of a UL128 complex and preventing CMV infection | |
TWI777093B (zh) | 非洲豬瘟病毒疫苗 | |
Anderholm et al. | Cytomegalovirus vaccines: current status and future prospects | |
US20040228842A1 (en) | Compositions and methods for cytomegalovirus treatment | |
JP2015505299A (ja) | サイトメガロウイルスの治療のための組成物及び方法 | |
US20150307850A1 (en) | Conditional replicating viral vectors | |
US20230323389A1 (en) | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines | |
US20210060155A1 (en) | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof | |
US11844833B2 (en) | Expression system for expressing herpesvirus glycoprotein complexes | |
WO2023077147A2 (en) | T-cell vaccines for patients with reduced humoral immunity | |
JP7317896B2 (ja) | 組換え改変ワクシニアウイルスアンカラ(mva)rsウイルス(rsv)ワクチン | |
US20220143174A1 (en) | Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof | |
WO2024003238A1 (en) | Epstein-barr-virus vaccine | |
Wussow et al. | Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170511 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181010 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6419695 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |